Thrombosis Research
Volume 125, Issue 3 , Pages 246-252 , March 2010

The effect of the long term aspirin administration on the progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse

  • Y. Yamamoto

      Affiliations

    • Laboratory of Physiology, Faculty of Nutrition, and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan
    • ,
  • T. Yamashita

      Affiliations

    • Laboratory of Physiology, Faculty of Nutrition, and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan
    • Corresponding Author InformationCorresponding author. Laboratory of Physiology, Faculty of Nutrition, Kobe Gakuin University, 518, Arise, Igawadani-Cho, Nishiku, Kobe, Japan 651-2180. Tel.: +81 78 974 1551; fax: +81 78 974 5689.
    • ,
  • F. Kitagawa

      Affiliations

    • Laboratory of Physiology, Faculty of Nutrition, and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan
    • ,
  • K. Sakamoto

      Affiliations

    • Laboratory of Physiology, Faculty of Nutrition, and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan
    • ,
  • J.C. Giddings

      Affiliations

    • Department of Haematology, Wales College of Medicine, Cardiff University, Cardiff, UK
    • ,
  • J. Yamamoto

      Affiliations

    • Laboratory of Physiology, Faculty of Nutrition, and Cooperative Research Center of Life Sciences, Kobe Gakuin University, Kobe, Japan

Received 26 March 2009 ,Revised 14 October 2009 ,Accepted 9 November 2009.

References 

  1. Bertrand ME. Provision of cardiovascular protection by ACE inhibitors: a review of recent trials. Curr Med Res Opin. 2004;20(10):1559–1569
  2. Napoli C, Lerman LO, de Nigris F, Gossl M, Balestrieri ML, Lerman A. Rethinking primary prevention of atherosclerosis-related diseases. Circulation. 2006;114(23):2517–2527
  3. Patel TN, Shishehbor MH, Bhatt DL. A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J. 2007;28(6):664–672
  4. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276(10):7614–7620
  5. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51(19):1829–1843
  6. Yamashita T, Oda E, Sano T, Ijiru Y, Giddings JC, Yamamoto J. Varying the ratio of dietary n-6/n-3 polyunsaturated fatty acid alters the tendency to thrombosis and progress of atherosclerosis in apoE-/- LDLR-/- double knockout mouse. Thromb Res. 2005;116(5):393–401
  7. Yamashita T, Shoge M, Oda E, Yamamoto Y, Giddings JC, Kashiwagi S, et al. The free-radical scavenger, edaravone, augments NO release from vascular cells and platelets after laser-induced, acute endothelial injury in vivo. Platelets. 2006;17(3):201–206
  8. Zhang X. Real time and in vivo monitoring of nitric oxide by electrochemical sensors–from dream to reality. Front Biosci. 2004;9:3434–3446
  9. Teraki Y, Moriya N, Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol. 1994;145(3):550–560
  10. Weiss EJ, Hamilton JR, Lease KE, Coughlin SR. Protection against thrombosis in mice lacking PAR3. Blood. 2002;100(9):3240–3244
  11. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325(16):1137–1141
  12. Witting PK, Pettersson K, Ostlund-Lindqvist AM, Westerlund C, Eriksson AW, Stocker R. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low density lipoprotein receptor gene double knockout mice. FASEB J. 1999;13(6):667–675
  13. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med. 1999;340(2):115–126
  14. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis. 1999;147(2):213–225
  15. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998;2(2):275–281
  16. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, et al. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97(7):1715–1722
  17. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest. 2001;107(6):675–683
  18. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5–6):255–258
  19. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A. 1998;95(22):13313–13318
  20. Kyrle PA, Minar E, Brenner B, Eichler HG, Heistinger M, Marosi L, et al. Thromboxane A2 and prostacyclin generation in the microvasculature of patients with atherosclerosis–effect of low-dose aspirin. Thromb Haemost. 1989;61(3):374–377
  21. Babaev VR, Ding L, Reese J, Morrow JD, Breyer MD, Dey SK, et al. Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation. 2006;113(1):108–117
  22. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115(10):1285–1295
  23. Coats P, Johnston F, MacDonald J, McMurray JJ, Hillier C. Endothelium-derived hyperpolarizing factor: identification and mechanisms of action in human subcutaneous resistance arteries. Circulation. 2001;103(12):1702–1708
  24. Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation. 1993;88(1):55–61
  25. Forstermann U, Mugge A, Alheid U, Haverich A, Frolich JC. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res. 1988;62(2):185–190
  26. Prasad K, Lee P. Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther. 2003;8(1):61–69
  27. Exner M, Hermann M, Hofbauer R, Kapiotis S, Speiser W, Held I, et al. The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS Lett. 2000;470(1):47–50
  28. Hsu CS, Li Y. Aspirin potently inhibits oxidative DNA strand breaks: implications for cancer chemoprevention. Biochem Biophys Res Commun. 2002;293(2):705–709
  29. Wijendran V, Hayes KC. Dietary n-6 and n-3 fatty acid balance and cardiovascular health. Annu Rev Nutr. 2004;24:597–615
  30. Stocker R, Keaney JF. Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84(4):1381–1478
  31. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007;115(16):2196–2207
  32. Hart RG, Harrison MJ. Aspirin wars: the optimal dose of aspirin prevent stroke. Stroke. 1996;27(4):585–587
  33. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297(18):2018–2024
  34. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300(18):2134–2141
  35. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation. 2008;117(2):296–329
  36. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366–1372
  37. Ferrell M, Fuster V, Gold HK, Chesebro JH. A dilemma for the 1990s. Choosing appropriate experimental animal model for the prevention of restenosis. Circulation. 1992;85(4):1630–1631

PII: S0049-3848(09)00509-X

doi: 10.1016/j.thromres.2009.11.008

Thrombosis Research
Volume 125, Issue 3 , Pages 246-252 , March 2010

Article Tools

* Image Usage & Resolution